Navigation Links
Specialists are Highly Satisfied with the Safety and Efficacy of Atripla and Isentress in the Treatment of HIV Patients
Date:3/11/2009

A CCR5 Antagonist That is Dosed Once Daily Could Earn an 18 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe, According to a New Report from Decision Resources

WALTHAM, Mass., March 11 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed infectious disease specialists identify a therapy's effect on the ability to achieve viral load suppression in treatment-naive patients as the attribute that most influences their prescribing decisions in HIV. Surveyed specialists indicate they are highly satisfied with Gilead/Bristol Myers Squibb's Atripla and Merck's Isentress in this attribute.

The new report entitled HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists finds that a novel drug in the CCR5 antagonist class that is dosed once daily and achieves maximum physician expectations would earn an 18 percent patient share in HIV in the United States and a 30 percent patient share in Europe, according to surveyed U.S. and European infectious disease specialists.

In 2008, Decision Resources' proprietary clinical gold standard for HIV was Merck's Isentress/Gilead's Truvada. Based on expert opinion, Isentress/Truvada will retain clinical gold standard status through 2017, owing to its balance of efficacy, novel mechanisms of action and safety. Although some therapies in development for HIV hold promise, most have efficacy, safety and tolerability, and/or delivery features that interviewed thought leaders believe are inferior when compared with Isentress/Truvada.

"Experts we surveyed rated Isentress plus Truvada as one of the safest antiretroviral regimens available," said Decision Resources Analyst Jose Avalos, Ph.D. "Furthermore, interviewed specialists believe Isentress' novel mechanism of action provides advantages in highly treatment experienced patients."

About the Report

HIV: Opportunity lies for Drug Developers in Integrase Inhibitors and Next Generation CCR5 Antagonists is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                            Decision Resources, Inc.
    Christopher Comfort                           Elizabeth Marshall
    781-296-2597                                  781-296-2563
    ccomfort@dresources.com                       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. For Primary Care, More Patients Are Seeing Specialists
2. Specialists On Call Earns the Hospital Association of Southern Californias Endorsement
3. Specialists On Call Expands Access to Emergency Neurology On-Call Services in Montana
4. Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Virginia
5. Wound Care Certification Course Endorsed by the American College of Certified Wound Specialists
6. Specialists On Call Expands Senior Management & Sales Teams
7. Texas Health Dallas New Intensivist Program Puts Critical-Care Specialists in the ICU - All the Time
8. Specialists On Call Accelerating Access to Emergency Neurology On-Call Services in Texas
9. Targeted Prostate Cancer Biopsy and Cancer Treatment Earns Acceptance From Nations Top Prostate Specialists
10. Gulf Coast Veterinary Specialists to Expand Comprehensive Eklin Digital Practice(R) Solutions
11. Medical Specialists of the Palm Beaches Selects Allscripts Electronic Health Record to Connect and Automate 85 Physicians
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Serenity Recovery, ... another video highlighting one of the many supplemental program options offered at their ... a 5 th Degree Black Belt in the Shorin-ryu style of Karate that ...
(Date:5/25/2016)... ... May 25, 2016 , ... The Horizon Foundation for ... pilot initiative to improve oral health-related awareness, education, prevention and treatment for young ... providers and promote best practices in 10 New Jersey counties where dental health ...
(Date:5/25/2016)... ... 2016 , ... New studies published today by the ... states. The outcomes examined in these studies include recovery of physical health and ... medical care. , “The goal of the studies is to provide information about ...
(Date:5/25/2016)... ... May 25, 2016 , ... Cheryl Bowker of Bowker ... bestow: the Dick McKenna Good Hands Legacy Award. McKenna ran one of Allstate’s most ... continues to inspire all those who knew him. The award named for him is ...
(Date:5/25/2016)... ... ... Casa Velas, an adults-only boutique hotel in Puerto Vallarta, Mexico, introduces a ... wellness suites . The two 1,350 sq. ft. suites which debuted in late 2015 ... amenities, from a custom soap selection and in-suite exercise kit to a personal wellness ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... May 23, 2016 According ... Share, Development, Growth and Demand Forecast to 2022 ... Other), by Application (Drug Discovery and Development, Proteomics, ... (Pharmaceuticals, Life Science and Biotechnology, Academic and Research ... Research, the global mass spectrometry market ...
(Date:5/23/2016)... -- The World Health Organization (WHO) expanded the Intended Use ... aged 13 years, and above. Effective immediately, the PrePex device, ... adolescent males in the 14 priority countries in Southern and ... male circumcision device to receive WHO Prequalification on 31 May ... said: " The expanded use of PrePex for ...
(Date:5/23/2016)... UAE, May 23, 2016 Experts ... of Precision Medicine and the role of technology ...   The First International Conference of VPS-Penn Medicine ... distinguished patronage and presence of Sheikh Nahyan bin Mubarak Al ... in Precision Medicine, which helps provide personalized medicine and tailor-made ...
Breaking Medicine Technology: